Andrea Ellis, Director at BridgeBio Pharma, Inc. (BBIO), sold 60,000 shares at $34.05 ($2.0M) on 2025-04-01, disclosed to the SEC on 2025-04-03.
Scheduled sale ($2.0M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.05 | 30,000 | $1.0M | 50.0% |
| 2 | $34.05 | 30,000 | $1.0M | 50.0% |
| Total | $34.05 avg | 60,000 | $2.0M | 100% |
| Filing → |
| BBIO | SELL | 2025-08-07 | $841K | — | Filing → |
| BBIO | SELL | 2025-04-16 | $350K | — | Filing → |
| BBIO | BUY | 2022-03-17 | $101K | — | Filing → |